Previous close | 8.50 |
Open | 8.50 |
Bid | 0.00 |
Ask | 0.00 |
Strike | 720.00 |
Expiry date | 2025-01-17 |
Day's range | 8.50 - 8.50 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Oral presentation to highlight activity of REGN7075 in combination with Libtayo from dose-escalation portion of trial in patients with microsatellite stable colorectal cancer, which has historically proven unresponsive to immunotherapy Ongoing REGN7075 Phase 1/2 trial is investigating a potentially first-in-class combination across a range of advanced solid tumors TARRYTOWN, N.Y., May 23, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive new results
Key Insights Regeneron Pharmaceuticals' estimated fair value is US$1,903 based on 2 Stage Free Cash Flow to Equity...
NOTUS results confirm landmark data from the Phase 3 BOREAS trial and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type 2 inflammation Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD TARRYTOWN, N.Y. and PARIS, May 20, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, I